Utility of the Hemangioma Severity Scale as a Triage Tool and Predictor of Need for Treatment

Mull, Jamie L.; Chamlin, Sarah L.; Lai, Jin‐Shei; Beaumont, Jennifer L.; Cella, David; Rancour, Elizabeth A.; Baselga, Eulàlia; Haggstrom, Anita N.

doi:10.1111/pde.13032

Cited by 13 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the study was performed in a reference centre where severe IHs were more likely to be referred. Nevertheless, our cohort seems to be comparable with other studies in terms of percentages of those treated for IHs (~10%), gender ratio (most were female), predominant location being on the head (nearly 80%), date of onset, predominant clinical subtype and indications for OP …”

Section: Discussionsupporting

confidence: 85%

Factors associated with delayed referral for infantile hemangioma necessitating propranolol

Onnis

Dreyfus

Mazereeuw‐Hautier

2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Factors associated with delayed referral for infantile hemangioma necessitating propranolol

Onnis

Dreyfus

Mazereeuw‐Hautier

2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…15 Furthermore, although the HSS was used to assist IH treatment decisions or referral, the cutoff values used for decision-making were inconsistent. 16,17 The current study had some limitations. One of the constraints of conducting a real-world observational study was that the representativeness of the participating physicians was potentially limited, restricting generalizability.…”

Section: Figurementioning

confidence: 93%

The Infantile Hemangioma Referral Score: A Validated Tool for Physicians

et al. 2020

View full text Add to dashboard Cite

and Troilius Rubin created the Infantile Hemangioma Referral Score tool, selected the 42 clinical cases for validating the tool (stage 1), and validated the study design; Drs van der Vleuten and Roessler participated in the validation of the gold standard (stage 2); and all authors discussed and validated the study results (including the choice of the threshold), reviewed and validated the manuscript, approved the final manuscript as submitted, and agree to be accountable for all aspects of the work.

show abstract

“…Step 2: Completion of the IHReS questionnaire Open access study also revealed the cut-off values of IHs with total HSS scores of 6 or greater should be referred for subspecialty evaluation. 15 As a triage purpose, the HSS may be a useful tool for primary care physicians in identifying high-risk IHs that may benefit from therapy. The HSS is a one-page scale with scoring items that require thorough information to complete the total score.…”

Section: Discussionmentioning

confidence: 99%

Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment

Chitpiromsak

Techasatian

Jetsrisuparb

2021

bmjpo

View full text Add to dashboard Cite

BackgroundThe general paediatricians and primary care physicians sometimes face immense difficulty in referral judgements regarding which infantile hemangiomas (IHs) require referrals and when is the appropriate time to refer IHs for treatment. This resulted in the treatment being delayed beyond IHs’ critical timeframe. The Infantile Hemangioma Referral Score (IHReS) has been recently developed, with the aim to solve this problem.ObjectivesThe objective of the present study is to evaluate the reliability of IHReS and to assess the possibility of using this instrument in our country where a similar problem of delaying treatment of IHs is currently existing.MethodsThe present study was a prospective, cross-sectional study. Thirteen selected clinical cases were used to assess the reliability of IHReS among physicians who may have had the chance to deal with patients with IHs. The target physicians across the country were asked to participate in the study via an online platform (Google Forms) to decide whether to refer patients with IHs for treatment or observe. There were 3 steps of assessment: step 1, usual practice evaluation; step 2, using IHReS; step 3, retesting by using IHReS.ResultsSubstantial agreement was observed after using IHReS (step 2) for interrater reliability, with Fleiss’ Kappa values of 0.80 and 0.78 among IH experts and non-expert physicians, respectively. Regarding repeatability, in the test–retest assessments, Cohen’s Kappa coefficient values revealed almost perfect agreement in intrarater repeatability for both experts and non-expert physicians (1.00).ConclusionIHReS is a simple, easy-to-assess tool for non-expert physicians. The benefit in the increase of interrater agreement was found in both IH experts and non-expert physicians. It has had the reliability to be used in making referral decisions regarding patients with IH for treatment among Thai physicians. Using IHReS can improve clinical outcomes by identifying which patient needs early intervention to minimise the possible complications.

show abstract

Utility of the Hemangioma Severity Scale as a Triage Tool and Predictor of Need for Treatment

Cited by 13 publications

References 14 publications

Factors associated with delayed referral for infantile hemangioma necessitating propranolol

Factors associated with delayed referral for infantile hemangioma necessitating propranolol

The Infantile Hemangioma Referral Score: A Validated Tool for Physicians

Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment

Contact Info

Product

Resources

About